Yellow fever vaccination as a model to study the response to stimulation of the inflammation system

Vascular Pharmacology

Volumn 39, Issue 3, 2002, Pages 117-121

  Van Der Beek, Martha T ^a   Visser, Leo G ^b   De Maat, Moniek P M ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Inflammation; Vaccination; Yellow fever

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; YELLOW FEVER VACCINE;

ADULT; AUTOMATION; BLOOD SAMPLING; CELL FRACTIONATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL MODEL; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOSTIMULATION; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; STIMULUS RESPONSE; VACCINATION; YELLOW FEVER;

ADULT; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 0344407038     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00297-5     Document Type: Conference Paper

References (14)

1. Hacker U.T., Jelinek T., Erhardt S., Eigler A., Hartmann G., Nothdurft H.D., Endres S. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J. Infect. Dis. 177:1998;774-778.
2. Lang J., Zuckerman J., Clarke P., Barrett P., Kirkpatrick C., Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. 60:1999;1045-1050.
3. Liuzzo G., Angiolillo D.J., Buffon A., Rizzello V., Colizzi C., Ginnetti F., Biasucci L.M., Maseri A. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation. 103:2001;2236-2241.
4. Monath T.P. Yellow Fever. 3:1999;815.
5. Montgomery H.E., Clarkson P., Nwose O.M., Mikailidis D.P., Jagroop I.A., Dollery C., Moult J., Benhizia F., Deanfield J., Jubb M. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscler. Thromb. Vasc. Biol. 16:1996;386-391.
6. Reinhardt B., Jaspert R., Niedrig M., Kostner C., L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56:1998;159-167.
7. Ridker P.M. Novel risk factors and markers for coronary disease. Adv. Intern. Med. 45:2000;391-418.
8. Ridker P.M., Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J. Invest. Med. 46:1998;391-395.
9. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. published erratum appears in N. Engl. J. Med. 336:1997;973-979.
10. Roers A., Hochkeppel H.K., Horisberger M.A., Hovanessian A., Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J. Infect. Dis. 169:1994;807-813.
11. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332:1995;635-641.
12. Tracy R.P. Inflammation markers and coronary heart disease. Curr. Opin. Lipidol. 10:1999;435-441.
13. van Deventer S.J., Buller H.R., ten Cate J.W., Aarden L.A., Hack C.E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 76:1990;2520-2526.
14. van Gool J., van Vugt H., de Bont E. Alpha 2-macroglobulin and fibrinogen modulate inflammatory edema in man. Inflammation. 14:1990;275-283.